Cord blood and tissue banking is the collection and preservation of the valuable cells within the umbilical cord of a newborn for future medical use. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years. Today, more than 70% of the global cord blood market is controlled by the world’s ten largest cord blood banking operators. [Read more…]
Stem Cells and Aging: What’s the Connection?
Most people are interested in healthy aging, longevity and a long life span. These pursuits are intrinsic to optimizing the human experience.
In our quest for tools and technologies to support this aim, the scientific community has begun exploring the connection between stem cells and aging. Study after study is coming out delineating the paramount importance of stem cells in the aging process.
If you are into anti-aging research, stem cell therapy, and the intersection of these fields of research, then let’s dive in. [Read more…]
Cell Therapy CDMOs – Role Of Contract Manufacturing For Cell Therapies
Among cell therapy companies, the pressure to manufacture innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise, such as cell therapy contract and development manufacturing organizations (CDMOs). Currently, there are an incredible 135 different CDMOs specializing in manufacturing and clinical trial support for cell and gene therapy developers.
Benefits of partnering with a cell therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. [Read more…]
Axol Bioscience Secures SMART Grant to Accelerate the Development of a Commercial iPSC-Powered ALS Models
Axol Bioscience has been awarded a SMART Grant by Scottish Enterprise to Accelerate ALS Research through the development of ALS-related phenotypes using human iPSCs. This represents another significant step towards better disease modelling and ALS drug discovery.
The key objectives of this project are to:
- Develop a quality manufacturing system for iPSC-derived ALS relevant cell types
- Characterise and validate the cells using ALS relevant end points; TDP43 aggregation, Neurofilament Light elevation and Cryptic Exon Sequencing
- Develop and characterise an ALS co-culture model which includes motor neurons, microglia and astrocytes
- Commercialise an easy-to-use model system to drive forward ALS drug discovery
Interview with Patrick Lucy, President and CEO of Lykan Bioscience
This is an interview with Patrick Lucy, President and CEO of Lykan Bioscience. Lykan is an innovative cell therapy-focused contract development and manufacturing organization (CDMO) headquartered in Hopkinton, MA. In this interview, we discuss the vision of Lykan Bioscience, its innovative and agile approach to CDMO services, and the company’s future goals. Enjoy! [Read more…]
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 336
- Next Page »